Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC
“Continuation therapy with atezolizumab (Tecentriq) following progression on first-line chemo-immunotherapy produced promising efficacy and manageable safety in a small cohort of patients with extensive-stage small cell lung cancer (ES-SCLC), according to findings from a pooled analysis study published in Clinical and Experimental Medicine.”
Unraveling the genetic differences between LUAD and LUSC in lung cancer
“Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC). Despite their classification under the same umbrella, these two forms of lung cancer exhibit distinct genetic landscapes, therapeutic targets, and treatment responses.”
FDA Grants Rhenium Obisbemeda Orphan Drug Status for LM in Lung Cancer
“The FDA has granted orphan drug designation (ODD) to rhenium (186Re) obisbemeda for the potential treatment of patients with leptomeningeal metastases (LM) in patients with lung cancer. Rhenium obisbemeda is a novel, injectable radiotherapy. The agent was just evaluated in the phase 1/2a ReSPECT-LM trial (NCT05034497) for patients with LM, as well as in the in the phase 1/2 ReSPECT-GBM trial (NCT01906385) for patients with recurrent glioblastoma.”
A New PD-L1 Nanobody Enhances Cell Death in Lung Cancer In Vitro and In Vivo
“Conclusion: The new PD-L1 nanobody substantially improved upon the FDA-approved PD-L1 monoclonal antibody by surpassing the disadvantage of having large molecular weight (MW) and low tissue penetration. The cytotoxicity and antitumor ability of PD-L1 nanobody, in vitro and in vivo, also support its potential as a therapeutic agent for lung cancer immunotherapy.”
Lung cancer disparities in rural, persistent poverty counties: a secondary data analysis
“Conclusions: Smoking, lung cancer incidence, and lung cancer mortality are highest in counties that are both rural and persistent poverty, suggesting an urgent need to develop targeted lung cancer interventions in these communities.”
When ‘Acceptable’ is Unacceptable: A Call for Objectivity in Cancer Trial Results
““Tolerable.” “Manageable.” “Acceptable.” Those are terms that crop up often when researchers report on early-phase clinical trials of new treatments for lung cancer at medical conferences. But do terms like these accurately describe the side effects caused by experimental treatments?”
Can Systematic Immune Inflammation Predict Survival in Patients Receiving Immune Checkpoint Inhibitors for NSCLC?
“A high pretreatment systemic immune-inflammation index level is associated with worse survival outcomes in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors, according to a recent study.”
Video:
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
“Ensacove (ensartinib) has been approved by the Food and Drug Administration (FDA) for adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.”
Lung Cancer Cases Rising In Non-Smoking Women: Risk Factors & Causes
“According to the World Health Organisation’s cancer sector, the number of lung cancer diagnoses among nonsmokers is rising, particularly among women. As per the research published in The Lancet Respiratory Medicine, lung adenocarcinoma, the most prevalent form of lung cancer in nonsmokers, causes about 60% of lung cancer cases in women and 45% in men. Globally, there were about 2.5 million new instances of lung cancer detected in 2022, up 300,000 from 2020.”
